Mitochondrial dysfunction biotech Stealth BioTherapeutics files for a $86 million IPO
Stealth BioTherapeutics, a US-based mitochondrial dysfunction biotech in clinical trials, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Newton, MA-based company was founded in 2006 and plans to list on the Nasdaq under the symbol MITO. Stealth BioTherapeutics filed confidentially on October 26, 2018. Jefferies, Evercore ISI and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Mitochondrial dysfunction biotech Stealth BioTherapeutics files for a $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.